Rhythm Pharmaceuticals Stock: Bull Case Intact, But The Market Is Pricing In A Lot (RYTM)
· seekingalpha.com
Rhythm Pharmaceuticals is a Buy on 79.5% YoY IMCIVREE sales growth, though 27.4x trailing sales and costs raise execution risk. Read more on RYTM stock here.
Rhythm Pharmaceuticals Inc. ( RYTM ) stock has seen quite a bit of momentum since I last covered it. Shares are up about 30% on the 6-month chart here. But afte...